Does  ||| S:0 E:5 ||| FW
idiopathic  ||| S:5 E:16 ||| FW
REM  ||| S:16 E:20 ||| FW
sleep  ||| S:20 E:26 ||| FW
behavior  ||| S:26 E:35 ||| FW
disorder  ||| S:35 E:44 ||| FW
( ||| S:44 E:45 ||| -LRB-
iRBD ||| S:45 E:49 ||| NNP
)  ||| S:49 E:51 ||| -RRB-
really  ||| S:51 E:58 ||| RB
exist ||| S:58 E:63 ||| VB
?  ||| S:63 E:65 ||| .
What  ||| S:65 E:70 ||| WP
are  ||| S:70 E:74 ||| VBP
the  ||| S:74 E:78 ||| DT
potential  ||| S:78 E:88 ||| JJ
markers  ||| S:88 E:96 ||| NN
of  ||| S:96 E:99 ||| IN
neurodegeneration  ||| S:99 E:117 ||| NN
in  ||| S:117 E:120 ||| IN
iRBD ||| S:120 E:124 ||| JJ
?  ||| S:124 E:126 ||| .
REM  ||| S:126 E:130 ||| NNP
sleep  ||| S:130 E:136 ||| NN
behavior  ||| S:136 E:145 ||| NN
disorder  ||| S:145 E:154 ||| NN
( ||| S:154 E:155 ||| -LRB-
RBD ||| S:155 E:158 ||| NNP
)  ||| S:158 E:160 ||| -RRB-
may  ||| S:160 E:164 ||| MD
be  ||| S:164 E:167 ||| VB
idiopathic  ||| S:167 E:178 ||| NNS
or  ||| S:178 E:181 ||| CC
associated  ||| S:181 E:192 ||| VBN
with  ||| S:192 E:197 ||| IN
other  ||| S:197 E:203 ||| JJ
neurologic  ||| S:203 E:214 ||| JJ
disorders ||| S:214 E:223 ||| NNS
.  ||| S:223 E:225 ||| .
A  ||| S:225 E:227 ||| DT
strong  ||| S:227 E:234 ||| JJ
association  ||| S:234 E:246 ||| NN
between  ||| S:246 E:254 ||| IN
RBD  ||| S:254 E:258 ||| NNP
and  ||| S:258 E:262 ||| CC
Î±-synucleinopathies  ||| S:262 E:282 ||| NNP
has  ||| S:282 E:286 ||| VBZ
recently  ||| S:286 E:295 ||| RB
been  ||| S:295 E:300 ||| VBN
observed ||| S:300 E:308 ||| VBN
,  ||| S:308 E:310 ||| ,
with  ||| S:310 E:315 ||| IN
the  ||| S:315 E:319 ||| DT
parasomnia  ||| S:319 E:330 ||| NN
often  ||| S:330 E:336 ||| RB
heralding  ||| S:336 E:346 ||| VB
the  ||| S:346 E:350 ||| DT
clinical  ||| S:350 E:359 ||| JJ
onset  ||| S:359 E:365 ||| NN
of  ||| S:365 E:368 ||| IN
the  ||| S:368 E:372 ||| DT
neurodegenerative  ||| S:372 E:390 ||| JJ
disease ||| S:390 E:397 ||| NN
.  ||| S:397 E:399 ||| .
The  ||| S:399 E:403 ||| DT
idiopathic  ||| S:403 E:414 ||| JJ
form  ||| S:414 E:419 ||| NN
accounts  ||| S:419 E:428 ||| NNS
for  ||| S:428 E:432 ||| IN
up  ||| S:432 E:435 ||| RB
to  ||| S:435 E:438 ||| TO
60 ||| S:438 E:440 ||| CD
%  ||| S:440 E:442 ||| NN
of  ||| S:442 E:445 ||| IN
the  ||| S:445 E:449 ||| DT
cases  ||| S:449 E:455 ||| NNS
reported  ||| S:455 E:464 ||| VBD
in  ||| S:464 E:467 ||| IN
the  ||| S:467 E:471 ||| DT
three  ||| S:471 E:477 ||| CD
largest  ||| S:477 E:485 ||| JJS
series  ||| S:485 E:492 ||| NN
of  ||| S:492 E:495 ||| IN
patients  ||| S:495 E:504 ||| NNS
with  ||| S:504 E:509 ||| IN
RBD ||| S:509 E:512 ||| NNP
.  ||| S:512 E:514 ||| .
Some  ||| S:514 E:519 ||| DT
clinical  ||| S:519 E:528 ||| JJ
follow-up  ||| S:528 E:538 ||| JJ
studies  ||| S:538 E:546 ||| NNS
revealed  ||| S:546 E:555 ||| VBD
that  ||| S:555 E:560 ||| IN
a  ||| S:560 E:562 ||| DT
large  ||| S:562 E:568 ||| JJ
proportion  ||| S:568 E:579 ||| NN
of  ||| S:579 E:582 ||| IN
these  ||| S:582 E:588 ||| DT
patients  ||| S:588 E:597 ||| NNS
will  ||| S:597 E:602 ||| MD
eventually  ||| S:602 E:613 ||| RB
develop  ||| S:613 E:621 ||| VB
a  ||| S:621 E:623 ||| DT
parkinsonian  ||| S:623 E:636 ||| JJ
syndrome  ||| S:636 E:645 ||| NN
or  ||| S:645 E:648 ||| CC
a  ||| S:648 E:650 ||| DT
dementia  ||| S:650 E:659 ||| NN
of  ||| S:659 E:662 ||| IN
the  ||| S:662 E:666 ||| DT
Lewy  ||| S:666 E:671 ||| JJ
bodies  ||| S:671 E:678 ||| NNS
type  ||| S:678 E:683 ||| NN
in  ||| S:683 E:686 ||| IN
the  ||| S:686 E:690 ||| DT
years  ||| S:690 E:696 ||| NNS
following  ||| S:696 E:706 ||| VBG
the  ||| S:706 E:710 ||| DT
RBD  ||| S:710 E:714 ||| NNP
diagnosis ||| S:714 E:723 ||| NN
.  ||| S:723 E:725 ||| .
The  ||| S:725 E:729 ||| DT
estimated  ||| S:729 E:739 ||| JJ
10-year  ||| S:739 E:747 ||| JJ
risk  ||| S:747 E:752 ||| NN
of  ||| S:752 E:755 ||| IN
neurodegenerative  ||| S:755 E:773 ||| JJ
disease  ||| S:773 E:781 ||| NN
for  ||| S:781 E:785 ||| IN
idiopathic  ||| S:785 E:796 ||| JJ
RBD  ||| S:796 E:800 ||| NNP
is  ||| S:800 E:803 ||| VBZ
about  ||| S:803 E:809 ||| RB
40 ||| S:809 E:811 ||| CD
% ||| S:811 E:812 ||| NN
.  ||| S:812 E:814 ||| .
Moreover ||| S:814 E:822 ||| RB
,  ||| S:822 E:824 ||| ,
it  ||| S:824 E:827 ||| PRP
has  ||| S:827 E:831 ||| VBZ
been  ||| S:831 E:836 ||| VBN
reported  ||| S:836 E:845 ||| VBN
that  ||| S:845 E:850 ||| IN
the  ||| S:850 E:854 ||| DT
median  ||| S:854 E:861 ||| JJ
interval  ||| S:861 E:870 ||| NN
between  ||| S:870 E:878 ||| IN
RBD  ||| S:878 E:882 ||| NNP
and  ||| S:882 E:886 ||| CC
subsequent  ||| S:886 E:897 ||| JJ
neurologic  ||| S:897 E:908 ||| JJ
syndrome  ||| S:908 E:917 ||| NN
is  ||| S:917 E:920 ||| VBZ
25years ||| S:920 E:927 ||| CD
.  ||| S:927 E:929 ||| .
Several  ||| S:929 E:937 ||| JJ
studies  ||| S:937 E:945 ||| NNS
have  ||| S:945 E:950 ||| VBP
looked  ||| S:950 E:957 ||| VBN
at  ||| S:957 E:960 ||| IN
neurophysiologic  ||| S:960 E:977 ||| NN
and  ||| S:977 E:981 ||| CC
neuropsychological  ||| S:981 E:1000 ||| JJ
functions  ||| S:1000 E:1010 ||| NNS
in  ||| S:1010 E:1013 ||| IN
idiopathic  ||| S:1013 E:1024 ||| JJ
RBD  ||| S:1024 E:1028 ||| NNP
and  ||| S:1028 E:1032 ||| CC
have  ||| S:1032 E:1037 ||| VBP
found  ||| S:1037 E:1043 ||| VBN
evidence  ||| S:1043 E:1052 ||| NN
of  ||| S:1052 E:1055 ||| IN
CNS  ||| S:1055 E:1059 ||| NNP
dysfunction  ||| S:1059 E:1071 ||| NN
during  ||| S:1071 E:1078 ||| IN
both  ||| S:1078 E:1083 ||| DT
wakefulness  ||| S:1083 E:1095 ||| NN
and  ||| S:1095 E:1099 ||| CC
sleep  ||| S:1099 E:1105 ||| VB
in  ||| S:1105 E:1108 ||| IN
a  ||| S:1108 E:1110 ||| DT
variable  ||| S:1110 E:1119 ||| JJ
proportion  ||| S:1119 E:1130 ||| NN
of  ||| S:1130 E:1133 ||| IN
these  ||| S:1133 E:1139 ||| DT
patients ||| S:1139 E:1147 ||| NNS
,  ||| S:1147 E:1149 ||| ,
challenging  ||| S:1149 E:1161 ||| VBG
the  ||| S:1161 E:1165 ||| DT
concept  ||| S:1165 E:1173 ||| NN
of  ||| S:1173 E:1176 ||| IN
idiopathic  ||| S:1176 E:1187 ||| JJ
RBD ||| S:1187 E:1190 ||| NNP
.  ||| S:1190 E:1192 ||| .
Identifying  ||| S:1192 E:1204 ||| VBG
subjects  ||| S:1204 E:1213 ||| NNS
with  ||| S:1213 E:1218 ||| IN
a  ||| S:1218 E:1220 ||| DT
high  ||| S:1220 E:1225 ||| JJ
risk  ||| S:1225 E:1230 ||| NN
of  ||| S:1230 E:1233 ||| IN
developing  ||| S:1233 E:1244 ||| VBG
a  ||| S:1244 E:1246 ||| DT
neurodegenerative  ||| S:1246 E:1264 ||| JJ
process  ||| S:1264 E:1272 ||| NN
may  ||| S:1272 E:1276 ||| MD
be  ||| S:1276 E:1279 ||| VB
crucial  ||| S:1279 E:1287 ||| JJ
to  ||| S:1287 E:1290 ||| TO
develop  ||| S:1290 E:1298 ||| VB
early  ||| S:1298 E:1304 ||| JJ
intervention  ||| S:1304 E:1317 ||| NN
strategies ||| S:1317 E:1327 ||| NNS
.  ||| S:1327 E:1329 ||| .
Prospective  ||| S:1329 E:1341 ||| JJ
studies  ||| S:1341 E:1349 ||| NNS
in  ||| S:1349 E:1352 ||| IN
idiopathic  ||| S:1352 E:1363 ||| JJ
RBD  ||| S:1363 E:1367 ||| NNP
showed  ||| S:1367 E:1374 ||| VBD
that  ||| S:1374 E:1379 ||| DT
potential  ||| S:1379 E:1389 ||| JJ
markers  ||| S:1389 E:1397 ||| NN
of  ||| S:1397 E:1400 ||| IN
neurodegeneration  ||| S:1400 E:1418 ||| NNS
include ||| S:1418 E:1425 ||| VBP
:  ||| S:1425 E:1427 ||| :
( ||| S:1427 E:1428 ||| -LRB-
1 ||| S:1428 E:1429 ||| LS
)  ||| S:1429 E:1431 ||| -RRB-
marked  ||| S:1431 E:1438 ||| VBD
EEG  ||| S:1438 E:1442 ||| NNP
slowing  ||| S:1442 E:1450 ||| NN
on  ||| S:1450 E:1453 ||| IN
spectral  ||| S:1453 E:1462 ||| JJ
analysis ||| S:1462 E:1470 ||| NN
;  ||| S:1470 E:1472 ||| :
( ||| S:1472 E:1473 ||| -LRB-
2 ||| S:1473 E:1474 ||| LS
)  ||| S:1474 E:1476 ||| -RRB-
decreased  ||| S:1476 E:1486 ||| FW
striatal  ||| S:1486 E:1495 ||| FW
123I-FP-CIT  ||| S:1495 E:1507 ||| FW
binding  ||| S:1507 E:1515 ||| FW
and  ||| S:1515 E:1519 ||| CC
substantia  ||| S:1519 E:1530 ||| JJ
nigra  ||| S:1530 E:1536 ||| JJ
hyperechogenicity ||| S:1536 E:1553 ||| NN
;  ||| S:1553 E:1555 ||| :
( ||| S:1555 E:1556 ||| -LRB-
3 ||| S:1556 E:1557 ||| LS
)  ||| S:1557 E:1559 ||| -RRB-
impaired  ||| S:1559 E:1568 ||| VBN
olfactory  ||| S:1568 E:1578 ||| JJ
function ||| S:1578 E:1586 ||| NN
;  ||| S:1586 E:1588 ||| :
( ||| S:1588 E:1589 ||| -LRB-
4 ||| S:1589 E:1590 ||| LS
)  ||| S:1590 E:1592 ||| -RRB-
impaired  ||| S:1592 E:1601 ||| JJ
color  ||| S:1601 E:1607 ||| NN
vision ||| S:1607 E:1613 ||| NN
.  ||| S:1613 E:1615 ||| .
